ReviewThe Journal of clinical investigation2018
Role of prostanoids in gastrointestinal cancer.
Review in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 155 citations in OpenAlex.
- Ablation of prostaglandin ENature biomedical engineering · 2026Article
- Immunomodulatory Effects of Flavonoids in Colitis-Associated Colorectal Cancer.International journal of molecular sciences · 2026Review
- Reprogrammed Lipid Metabolism as a Gatekeeper of Hepatocarcinogenesis: from Enzyme Regulation to Precision Therapy.Current oncology reports · 2026Review
- Bridging aging and colorectal cancer: synergistic roles of inflammaging and immunosenescence.Frontiers in immunology · 2026Review
- Colorectal Cancer Progression and Bone Metastasis: Molecular Mechanisms, Tumor Microenvironment, and Tumor-Bone Crosstalk.Cancer management and research · 2026Review
- The dual pathological roles and targeted therapy of PGEFrontiers in pharmacology · 2026Review
- The Role of Prostaglandins as Major Inflammatory Mediators in Colorectal Cancer.International journal of molecular sciences · 2025Review
- Prostaglandin EProceedings of the National Academy of Sciences of the United States of America · 2025Article
- ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.Cancer science · 2025Article
- Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation.Cancer discovery · 2025Article
- Exploring the Molecular Mechanism of Hydroxychloroquine Against IgAN Through Network Pharmacology, MD Simulations and Experimental Assessment.Journal of cellular and molecular medicine · 2025Article
- Probiotics in colorectal cancer prevention and therapy: mechanisms, benefits, and challenges.Discover oncology · 2025Review
- Causal effect between circulating metabolic markers and glioma: a bidirectional, two-sample, Bayesian weighted Mendelian randomization.Discover oncology · 2025Article
- Advanced hierarchical computational modeling-based rational development of platinum (II) nanocomplex to improve lung cancer therapy.Advanced functional materials · 2025Article
- Cancer Development and Progression in Patients with Heart Failure.Current heart failure reports · 2024Review
- Therapeutic potential of Phycocyanin in gastrointestinal cancers and related disorders.Molecular biology reports · 2024Review
- Review
- Ginsenoside Rg5 as an anticancer drug: a comprehensive review on mechanisms, structure-activity relationship, and prospects for clinical advancement.Pharmacological reports : PR · 2024Review
- LRRK2 G2019S Promotes Colon Cancer Potentially via LRRK2-GSDMD Axis-Mediated Gut Inflammation.Cells · 2024Article
- Intraoperative Ketorolac and Outcomes after Ovarian Cancer Surgery.Journal of clinical medicine · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chronic inflammation is a risk factor for gastrointestinal cancer and other diseases. Most studies have focused on cytokines and chemokines as mediators connecting chronic inflammation to cancer, whereas the involvement of lipid mediators, including prostanoids, has not been extensively investigated. Prostanoids are among the earliest signaling molecules released in response to inflammation. Multiple lines of evidence suggest that prostanoids are involved in gastrointestinal cancer. In this Review, we discuss how prostanoids impact gastrointestinal cancer development. In particular, we highlight recent advances in our understanding of how prostaglandin E2 induces the immunosuppressive microenvironment in gastrointestinal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.